Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 503978, 5 pages
http://dx.doi.org/10.1155/2015/503978
Review Article

HIV Vaccine Research: The Challenge and the Way Forward

Zhuhai International Travel Healthcare Center, Zhuhai Entry-Exit Inspection and Quarantine Bureau, Zhuhai, Guangdong 519020, China

Received 25 September 2014; Revised 26 February 2015; Accepted 5 March 2015

Academic Editor: Stuart Berzins

Copyright © 2015 Hai-Bo Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. B. Sinoussi, J. C. Chermann, F. Rey et al., “Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS),” Science, vol. 220, no. 4599, pp. 868–871, 1983. View at Publisher · View at Google Scholar · View at Scopus
  2. R. C. Gallo, P. S. Sarin, E. P. Gelmann et al., “Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS),” Science, vol. 220, no. 4599, pp. 865–867, 1983. View at Publisher · View at Google Scholar · View at Scopus
  3. WHO, Data and Statistics, 2015, http://www.who.int/hiv/data/en/.
  4. D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz, “Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection,” Nature, vol. 373, no. 6510, pp. 123–126, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. F. J. Palella Jr., K. M. Delaney, A. C. Moorman et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators,” The New England Journal of Medicine, vol. 338, no. 13, pp. 853–860, 1998. View at Google Scholar
  6. R. P. Walensky, A. D. Paltiel, E. Losina et al., “The survival benefits of AIDS treatment in the United States,” Journal of Infectious Diseases, vol. 194, no. 1, pp. 11–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. D. D. Richman, D. M. Margolis, M. Delaney, W. C. Greene, D. Hazuda, and R. J. Pomerantz, “The challenge of finding a cure for HIV infection,” Science, vol. 323, no. 5919, pp. 1304–1307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Zagury, R. Léonard, M. Fouchard et al., “Immunization against AIDS in humans,” Nature, vol. 326, no. 6110, pp. 249–250, 1987. View at Publisher · View at Google Scholar · View at Scopus
  9. I. A. V. I. (IAVI), “Clinical trials database,” 2014, http://www.iavireport.org/Trials-Database.
  10. F. Miedema, “A brief history of HIV vaccine research: stepping back to the drawing board?” AIDS, vol. 22, no. 14, pp. 1699–1703, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. N. M. Flynn, D. N. Forthal, C. D. Harro et al., “Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection,” Journal of Infectious Diseases, vol. 191, no. 5, pp. 654–665, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Pitisuttithum, P. Gilbert, M. Gurwith et al., “Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand,” Journal of Infectious Diseases, vol. 194, no. 12, pp. 1661–1671, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. V. M. Hirsch, S. Goldstein, N. A. Hynes et al., “Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine,” Journal of Infectious Diseases, vol. 170, no. 1, pp. 51–59, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. J. W. Shiver, T. M. Fu, L. Chen et al., “Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity,” Nature, vol. 415, no. 6869, pp. 331–335, 2002. View at Google Scholar
  15. J. W. Shiver and E. A. Emini, “Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors,” Annual Review of Medicine, vol. 55, pp. 355–372, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. D. R. Casimiro, F. Wang, W. A. Schleif et al., “Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag,” Journal of Virology, vol. 79, no. 24, pp. 15547–15555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. S. Fauci, “The release of new data from the HVTN 502 (STEP) HIV vaccine study,” 2007, http://www3.niaid.nih.gov/news/newsreleases/2007/step_11707.htm.
  18. R. Steinbrook, “One step forward, two steps back—will there ever be an AIDS vaccine?” The New England Journal of Medicine, vol. 357, no. 26, pp. 2653–2655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Robertson, M. Mehrotra, D. Fitzgerald et al., “Efficacy results from the STEP study (Merck V520 protocol 023/HVTN502): a phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef trivalent vaccine,” in Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, Mass, USA, February 2008.
  20. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan et al., “Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand,” The New England Journal of Medicine, vol. 361, no. 23, pp. 2209–2220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. B. F. Haynes, P. B. Gilbert, M. J. McElrath et al., “Immune-correlates analysis of an HIV-1 vaccine efficacy trial,” The New England Journal of Medicine, vol. 366, no. 14, pp. 1275–1286, 2012. View at Publisher · View at Google Scholar
  22. D. D. Ho and P. D. Bieniasz, “HIV-1 at 25,” Cell, vol. 133, no. 4, pp. 561–565, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Gaschen, J. Taylor, K. Yusim et al., “Diversity considerations in HIV-1 vaccine selection,” Science, vol. 296, no. 5577, pp. 2354–2360, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. B. D. Walker and B. T. Korber, “Immune control of HIV: the obstacles of HLA and viral diversity,” Nature Immunology, vol. 2, no. 6, pp. 473–475, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. P. D. Kwong, R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson, “Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody,” Nature, vol. 393, no. 6686, pp. 648–659, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Wyatt, P. D. Kwong, E. Desjardins et al., “The antigenic structure of the HIV gp120 envelope glycoprotein,” Nature, vol. 393, no. 6686, pp. 705–711, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Chen, E. M. Vogan, H. Gong, J. J. Skehel, D. C. Wiley, and S. C. Harrison, “Structure of an unliganded simian immunodeficiency virus gp120 core,” Nature, vol. 433, no. 7028, pp. 834–841, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Flores, “Seeking new pathways for HIV vaccine discovery,” Future Microbiology, vol. 4, no. 1, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. R. E. Phillips, S. Rowland-Jones, D. F. Nixon et al., “Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition,” Nature, vol. 354, no. 6353, pp. 453–459, 1991. View at Publisher · View at Google Scholar · View at Scopus
  30. T. M. Allen, D. H. O'Connor, P. Jing et al., “Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia,” Nature, vol. 407, no. 6802, pp. 386–390, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. D. H. Barouch, J. Kunstman, M. J. Kuroda et al., “Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes,” Nature, vol. 415, no. 6869, pp. 335–339, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. D. H. Barouch, “Challenges in the development of an HIV-1 vaccine,” Nature, vol. 455, no. 7213, pp. 613–619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. D. Daniel, F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers, “Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene,” Science, vol. 258, no. 5090, pp. 1938–1941, 1992. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Murphey-Corb, L. N. Martin, B. Davison-Fairburn et al., “A formalin-inactivated whole SIV vaccine confers protection in macaques,” Science, vol. 246, no. 4935, pp. 1293–1297, 1989. View at Publisher · View at Google Scholar · View at Scopus
  35. T. W. Baba, V. Liska, A. H. Khimani et al., “Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques,” Nature Medicine, vol. 5, no. 2, pp. 194–203, 1999. View at Google Scholar
  36. W. Fischer, S. Perkins, J. Theiler et al., “Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants,” Nature Medicine, vol. 13, no. 1, pp. 100–106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Gao, E. A. Weaver, Z. Lu et al., “Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein,” Journal of Virology, vol. 79, no. 2, pp. 1154–1163, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. H.-X. Liao, C.-Y. Tsao, S. Munir Alam et al., “Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1,” Journal of Virology, vol. 87, no. 8, pp. 4185–4201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. D. H. Barouch, K. L. O'Brien, N. L. Simmons et al., “Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys,” Nature Medicine, vol. 16, no. 3, pp. 319–323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Santra, H.-X. Liao, R. Zhang et al., “Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys,” Nature Medicine, vol. 16, no. 3, pp. 324–328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. D. H. Barouch, K. E. Stephenson, E. N. Borducchi et al., “Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys,” Cell, vol. 155, no. 3, pp. 531–539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Palesch and F. Kirchhoff, “First steps toward a globally effective HIV/AIDS vaccine,” Cell, vol. 155, no. 3, pp. 495–497, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. H. X. Liao, R. Lynch, T. Zhou et al., “Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus,” Nature, vol. 496, no. 7446, pp. 469–476, 2013. View at Google Scholar
  44. J. Jardine, J. P. Julien, S. Menis et al., “Rational HIV immunogen design to target specific germline B cell receptors,” Science, vol. 340, no. 6133, pp. 711–716, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. A. T. McGuire, S. Hoot, A. M. Dreyer et al., “Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies,” The Journal of Experimental Medicine, vol. 210, no. 4, pp. 655–663, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. D. L. Sodora, J. S. Allan, C. Apetrei et al., “Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts,” Nature Medicine, vol. 15, no. 8, pp. 861–865, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Pulendran and R. Ahmed, “Translating innate immunity into immunological memory: implications for vaccine development,” Cell, vol. 124, no. 4, pp. 849–863, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. R. J. Shattock, B. F. Haynes, B. Pulendran, J. Flores, and J. Esparza, “Improving defences at the portal of HIV entry: mucosal and innate immunity: a summary report from a Global HIV Vaccine Enterprise working group,” PLoS Medicine, vol. 5, no. 4, article e81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Sui, S. Gordon, G. Franchini, and J. A. Berzofsky, “UNIT 12.14 Nonhuman primate models for HIV/AIDS vaccine development,” Current Protocols in Immunology, 2013. View at Publisher · View at Google Scholar
  50. NIH, “NIH Discontinues Immunizations in HIV Vaccine Study,” June 2014, http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013.aspx.
  51. P. B. Gilbert, J. O. Berger, D. Stablein et al., “Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials,” Journal of Infectious Diseases, vol. 203, no. 7, pp. 969–975, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. K. E. Stephenson and D. H. Barouch, “A global approach to HIV-1 vaccine development,” Immunological Reviews, vol. 254, no. 1, pp. 295–304, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. T. A. Day and J. G. Kublin, “Lessons learned from HIV vaccine clinical efficacy trials,” Current HIV Research, vol. 11, no. 6, pp. 441–449, 2013. View at Google Scholar · View at Scopus